XML 46 R36.htm IDEA: XBRL DOCUMENT v3.25.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Astellas Gene Therapies, Inc. (Details)
 1 Months Ended 3 Months Ended
Dec. 31, 2024
USD ($)
target
indication
Aug. 31, 2024
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues     $ 6,437,000 $ 481,000
Deferred revenues $ 7,556,000   7,556,000  
Deferred revenues, non-current $ 5,874,000   5,874,000  
Astellas Gene Therapies, Inc. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Royalty obligation, term   10 years    
License | Astellas Gene Therapies, Inc. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Number of additional targets | target 4      
Number of indications per target | indication 3      
Agreement term 3 years      
Contract with customer liability $ 20,000,000      
Variable consideration amount $ 1,300,000,000      
Number of targets | target 5      
Initial License | Astellas Gene Therapies, Inc. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Contract with customer liability $ 6,500,000      
Revenues 6,500,000      
Additional Licenses | Astellas Gene Therapies, Inc. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Contract with customer liability $ 13,500,000   13,500,000  
Revenues     0 $ 0
Deferred revenues     7,600,000  
Underlying options, exercise or expiration term 4 years      
Deferred revenues, non-current     $ 5,900,000